减少癫痫试验中的安慰剂暴露:研究圆桌会议考量
本文基于2016年癫痫研究圆桌会议,讨论减少癫痫注册试验中安慰剂暴露的新设计。会议引用荟萃分析显示安慰剂或无效剂量组癫痫猝死率增加3至5倍,并综述了主动对照附加试验、时间事件设计、适应性设计等多种替代方案的优缺点。
要点
- 癫痫附加试验中约6个月的安慰剂暴露可能增加癫痫猝死风险。
- 荟萃分析显示安慰剂或无效剂量组癫痫猝死率增加3至5倍。
- 多种替代设计各有优劣,需在整体研发计划中权衡安全性与证据严谨性。
核心结论
- 可考虑将减少安慰剂暴露的新设计加入整体研发计划,使试验对参与者更安全同时仍提供严谨疗效证据。
研究设计与样本
- 2016年5月19-20日癫痫研究圆桌会议首次会议,聚焦减少癫痫临床试验中的安慰剂暴露。
主要发现
- 荟萃分析显示随机分配至安慰剂或新抗癫痫药无效剂量的参与者癫痫猝死率增加3至5倍。
关键数值与推荐
- 癫痫附加注册试验中安慰剂暴露通常约6个月。
临床怎么用
- 在癫痫注册试验整体开发计划中,可评估主动对照附加试验、时间事件设计、适应性设计、平台试验合并安慰剂对照、药代/药效学方法及排除药物耐受后的短期试验等替代设计。
局限性
- 会议讨论了每种设计的优点与局限性,但原文未报告具体推荐阈值或实施标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The randomized controlled trial is the unequivocal gold standard for demonstrating clinical efficacy and safety of investigational therapies. Recently there have been concerns raised about prolonged exposure to placebo and ineffective therapy during the course of an add-on regulatory trial for new antiepileptic drug approval (typically ∼6 months in duration), due to the potential risks of continued uncontrolled epilepsy for that period. The first meeting of the Research Roundtable in Epilepsy on May 19-20, 2016, focused on "Reducing placebo exposure in epilepsy clinical trials," with a goal of considering new designs for epilepsy regulatory trials that may be added to the overall development plan to make it, as a whole, safer for participants while still providing rigorous evidence of effect. This topic was motivated in part by data from a meta-analysis showing a 3- to 5-fold increased rate of sudden unexpected death in epilepsy in participants randomized to placebo or ineffective doses of new antiepileptic drugs. The meeting agenda included rationale and discussion of different trial designs, including active-control add-on trials, placebo add-on to background therapy with adjustment, time to event designs, adaptive designs, platform trials with pooled placebo control, a pharmacokinetic/pharmacodynamic approach to reducing placebo exposure, and shorter trials when drug tolerance has been ruled out. The merits and limitations of each design were discussed and are reviewed here.
引用
- Fureman BE, Friedman D, Baulac M, et al. Reducing placebo exposure in trials: Considerations from the Research Roundtable in Epilepsy. Neurology. 2017. PMID: 28878049. doi:10.1212/WNL.0000000000004535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。